R2810-ONC-2251 Enrolling

Cutaneous Squamous Cell Carcinoma Study* (36 Months)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults (≥18 years old) with cutaneous squamous cell carcinoma can participate.

Inclusion Criteria

  • invasive cutaneous squamous cell carcinoma (CSCC)
  • have a CSCC lesion between 1 – 2 cm in diameter located on either the head, neck, hand, or shin

          Note: There are additional study inclusion & exclusion criterias.

Participant Information

  • Participate and receive study treatment at no cost
  • Regular visits with study doctors who specialise in treating cutaneous squamous cell carcinoma (18 visits)
  • Will receive either an investigative injection treatment (study drug) or a placebo
  • Reimbursement for study-related expenses will be provided (as specifically defined in the consent form)

How Long Will The Study Last?

  • 156 weeks

Participating Locations

COUNTRY
country-icon
Australia

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: August 14, 2025

Official Title

A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)

ClinicalTrials.gov ID

NCT06585410

Sponsor

Regeneron Pharmaceuticals

Study Description

  • Brief Summary:

    This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works

  • Condition or Disease:

    Cutaneous Squamous Cell Carcinoma (CSCC)

  • Intervention/Treatment:

    Drug: Cemiplimab Procedure: Standard of care
  • Phase:

    PHASE3

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Squamous Cell Carcinoma

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content